Rel-(3R,4R)-3-(5,6-Dihydro-4H-Pyrrolo[3,2,1-Ij]Quinolin-1-Yl)-4-(1H-Indol-3-Yl)-2,5-Pyrrolidinedione structure
|
Common Name | Rel-(3R,4R)-3-(5,6-Dihydro-4H-Pyrrolo[3,2,1-Ij]Quinolin-1-Yl)-4-(1H-Indol-3-Yl)-2,5-Pyrrolidinedione | ||
---|---|---|---|---|
CAS Number | 905853-99-8 | Molecular Weight | 369.42 | |
Density | 1.49±0.1 g/cm3(Predicted) | Boiling Point | 715.9±60.0 °C(Predicted) | |
Molecular Formula | C23H19N3O2 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 386.8±32.9 °C |
Use of Rel-(3R,4R)-3-(5,6-Dihydro-4H-Pyrrolo[3,2,1-Ij]Quinolin-1-Yl)-4-(1H-Indol-3-Yl)-2,5-Pyrrolidinedione(rel)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (rel)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC)[1]. |
Name | 2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)-rel- |
---|---|
Synonym | More Synonyms |
Description | (rel)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (rel)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC)[1]. |
---|---|
Related Catalog | |
References |
Density | 1.49±0.1 g/cm3(Predicted) |
---|---|
Boiling Point | 715.9±60.0 °C(Predicted) |
Molecular Formula | C23H19N3O2 |
Molecular Weight | 369.42 |
Flash Point | 386.8±32.9 °C |
Exact Mass | 369.147736 |
LogP | 3.26 |
Vapour Pressure | 0.0±2.3 mmHg at 25°C |
Index of Refraction | 1.797 |
Storage condition | 2-8°C |
(3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione |
(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione |
9326 |
PJ4H73IL17 |
(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]chinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidin-2,5-dion |
ARQ 197 |
MFCD11977597 |
2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)- |
Tivantinib |
ARQ-197 |